Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ERICH1-DPYD

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ERICH1-DPYD
	FusionPDB ID: 27403
	FusionGDB2.0 ID: 27403
		Hgene	Tgene
	Gene symbol	ERICH1	DPYD
	Gene ID	157697	1806
	Gene name	glutamate rich 1	dihydropyrimidine dehydrogenase
	Synonyms	HSPC319	DHP\|DHPDHASE\|DPD
	Cytomap	8p23.3	1p21.3
	Type of gene	protein-coding	protein-coding
	Description	glutamate-rich protein 1	dihydropyrimidine dehydrogenase [NADP(+)]dihydrothymine dehydrogenasedihydrouracil dehydrogenase
	Modification date	20200313	20200313
	UniProtAcc	Q86X53 Main function of 5'-partner protein:	Q12882 Main function of 5'-partner protein: FUNCTION: Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000262109, ENST00000522706, ENST00000518277,	ENST00000306031, ENST00000423006, ENST00000474241, ENST00000370192,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	8 X 6 X 6=288	12 X 12 X 7=1008
	# samples	8	13
	** MAII score	log2(8/288*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(13/1008*10)=-2.95491211047146 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ERICH1 [Title/Abstract] AND DPYD [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ERICH1 [Title/Abstract] AND DPYD [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ERICH1(618598)-DPYD(97700550), # samples:1
Anticipated loss of major functional domain due to fusion event.	ERICH1-DPYD seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ERICH1-DPYD seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ERICH1-DPYD seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ERICH1-DPYD seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	DPYD	GO:0006210	thymine catabolic process	10410956
Tgene	DPYD	GO:0006212	uracil catabolic process	1512248\|18075467
Tgene	DPYD	GO:0006214	thymidine catabolic process	1512248

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:618598/chr1:97700550)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ERICH1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across DPYD (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000522706	ERICH1	chr8	618598	-	ENST00000370192	DPYD	chr1	97700550	-	3024	1012	12	1790	592
ENST00000262109	ERICH1	chr8	618598	-	ENST00000370192	DPYD	chr1	97700550	-	3348	1336	54	2114	686

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000522706	ENST00000370192	ERICH1	chr8	618598	-	DPYD	chr1	97700550	-	0.00094205	0.99905795
ENST00000262109	ENST00000370192	ERICH1	chr8	618598	-	DPYD	chr1	97700550	-	0.000825409	0.99917454

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ERICH1-DPYD

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ERICH1	chr8	618598	DPYD	chr1	97700550	1012	333	ALEMFPEHCTMPPGTAIRPIALRAVT
ERICH1	chr8	618598	DPYD	chr1	97700550	1336	427	ALEMFPEHCTMPPGTAIRPIALRAVT

Top

Potential FusionNeoAntigen Information of ERICH1-DPYD in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ERICH1-DPYD_618598_97700550.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:05	TMPPGTAIR	0.9516	0.6749	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B15:16	CTMPPGTAI	0.9448	0.9931	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:03	TMPPGTAIR	0.9411	0.6581	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A34:01	TMPPGTAIR	0.9375	0.6282	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A34:05	TMPPGTAIR	0.9375	0.6282	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A31:02	TMPPGTAIR	0.844	0.8497	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A33:01	TMPPGTAIR	0.821	0.5327	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A33:05	TMPPGTAIR	0.821	0.5327	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A66:03	TMPPGTAIR	0.681	0.5294	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B52:01	CTMPPGTAI	0.6719	0.9983	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A26:03	TMPPGTAIR	0.6575	0.5119	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:24	CTMPPGTAIR	0.9956	0.6407	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A66:01	CTMPPGTAIR	0.9939	0.7122	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:03	CTMPPGTAIR	0.9934	0.6189	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A11:10	CTMPPGTAIR	0.9919	0.5499	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:08	CTMPPGTAIR	0.9889	0.7028	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:05	CTMPPGTAIR	0.9858	0.6249	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A34:01	CTMPPGTAIR	0.9855	0.6999	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A34:05	CTMPPGTAIR	0.9855	0.6999	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A31:06	CTMPPGTAIR	0.9749	0.7963	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A66:03	CTMPPGTAIR	0.9733	0.6309	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:06	EHCTMPPGTA	0.9649	0.9614	6	16
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:06	CTMPPGTAIR	0.9544	0.681	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A34:02	CTMPPGTAIR	0.9541	0.6939	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A74:03	CTMPPGTAIR	0.9328	0.8565	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A74:11	CTMPPGTAIR	0.9328	0.8565	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A74:09	CTMPPGTAIR	0.9328	0.8565	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A31:02	CTMPPGTAIR	0.9324	0.8268	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:02	MPPGTAIRPI	0.9315	0.7836	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A33:01	CTMPPGTAIR	0.9293	0.6507	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A33:05	CTMPPGTAIR	0.9293	0.6507	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:01	MPPGTAIRPI	0.8837	0.8426	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:01	EHCTMPPGTAI	0.9993	0.994	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:24	EHCTMPPGTAI	0.9989	0.9333	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B38:02	EHCTMPPGTAI	0.9984	0.9979	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B38:01	EHCTMPPGTAI	0.9984	0.9976	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:06	EHCTMPPGTAI	0.9981	0.9847	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B56:01	MPPGTAIRPIA	0.9965	0.6467	10	21
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B15:10	EHCTMPPGTAI	0.9881	0.9193	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B15:37	EHCTMPPGTAI	0.9073	0.9471	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B07:10	EHCTMPPGTAI	0.7543	0.6437	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C01:30	TMPPGTAI	0.9627	0.9832	9	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C01:17	TMPPGTAI	0.9486	0.9821	9	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:06	CTMPPGTAI	0.9985	0.9866	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:04	CTMPPGTAI	0.9985	0.9848	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:07	CTMPPGTAI	0.9983	0.9951	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:19	CTMPPGTAI	0.9928	0.9982	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:08	CTMPPGTAI	0.9892	0.9868	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C08:04	CTMPPGTAI	0.9461	0.9922	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C08:13	CTMPPGTAI	0.9461	0.9922	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C12:12	CTMPPGTAI	0.9349	0.9752	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C02:06	CTMPPGTAI	0.9109	0.9933	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:01	CTMPPGTAIR	0.9956	0.6407	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A33:03	CTMPPGTAIR	0.9695	0.5684	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A31:01	CTMPPGTAIR	0.9598	0.8367	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:06	HCTMPPGTAI	0.957	0.9855	7	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:08	MPPGTAIRPI	0.8079	0.7176	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B54:01	MPPGTAIRPIA	0.9994	0.9149	10	21
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:12	EHCTMPPGTAI	0.9992	0.9946	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:09	EHCTMPPGTAI	0.9991	0.9674	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:05	EHCTMPPGTAI	0.9986	0.9924	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B14:03	EHCTMPPGTAI	0.9406	0.991	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C01:03	TMPPGTAI	0.9496	0.9582	9	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C01:02	TMPPGTAI	0.9406	0.9814	9	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:02	CTMPPGTAI	0.9986	0.9866	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:05	CTMPPGTAI	0.9985	0.9831	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C15:09	CTMPPGTAI	0.9985	0.9848	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:05	CTMPPGTAI	0.9934	0.9824	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:17	CTMPPGTAI	0.9904	0.9938	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:03	CTMPPGTAI	0.9844	0.9979	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:04	CTMPPGTAI	0.9844	0.9979	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:02	CTMPPGTAI	0.9815	0.941	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C03:06	CTMPPGTAI	0.9775	0.998	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A69:01	CTMPPGTAI	0.9518	0.8922	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A66:02	TMPPGTAIR	0.8308	0.526	9	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B07:13	CTMPPGTAI	0.7442	0.8529	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-C17:01	CTMPPGTAI	0.6163	0.9892	8	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A66:02	CTMPPGTAIR	0.9837	0.6155	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A74:01	CTMPPGTAIR	0.9328	0.8565	8	18
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:13	MPPGTAIRPI	0.8726	0.7737	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:14	MPPGTAIRPI	0.8719	0.825	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:09	MPPGTAIRPI	0.8672	0.7712	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B51:29	MPPGTAIRPI	0.8263	0.656	10	20
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:02	HCTMPPGTAI	0.6077	0.9555	7	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A69:01	HCTMPPGTAI	0.4403	0.8959	7	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:31	EHCTMPPGTAI	0.9994	0.994	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B38:05	EHCTMPPGTAI	0.9984	0.9976	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B55:02	MPPGTAIRPIA	0.9935	0.704	10	21
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B39:11	EHCTMPPGTAI	0.9927	0.9801	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-B15:09	EHCTMPPGTAI	0.9878	0.9607	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A68:02	EHCTMPPGTAI	0.9611	0.973	6	17
ERICH1-DPYD	chr8	618598	chr1	97700550	1336	HLA-A69:01	EHCTMPPGTAI	0.9253	0.9568	6	17

Top

Potential FusionNeoAntigen Information of ERICH1-DPYD in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ERICH1-DPYD

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1776	EHCTMPPGTAIRPI	ERICH1	DPYD	chr8	618598	chr1	97700550	1336

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ERICH1-DPYD

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1776	EHCTMPPGTAIRPI	-7.9962	-8.1096
HLA-B14:02	3BVN	1776	EHCTMPPGTAIRPI	-5.70842	-6.74372
HLA-B52:01	3W39	1776	EHCTMPPGTAIRPI	-6.83737	-6.95077
HLA-B52:01	3W39	1776	EHCTMPPGTAIRPI	-4.4836	-5.5189
HLA-A11:01	4UQ2	1776	EHCTMPPGTAIRPI	-10.0067	-10.1201
HLA-A11:01	4UQ2	1776	EHCTMPPGTAIRPI	-9.03915	-10.0745
HLA-A24:02	5HGA	1776	EHCTMPPGTAIRPI	-6.56204	-6.67544
HLA-A24:02	5HGA	1776	EHCTMPPGTAIRPI	-5.42271	-6.45801
HLA-B44:05	3DX8	1776	EHCTMPPGTAIRPI	-7.85648	-8.89178
HLA-B44:05	3DX8	1776	EHCTMPPGTAIRPI	-5.3978	-5.5112
HLA-A02:01	6TDR	1776	EHCTMPPGTAIRPI	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ERICH1-DPYD

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ERICH1-DPYD	chr8	618598	chr1	97700550	10	20	MPPGTAIRPI	TGCCTCCTGGGACAGCAATCAGACCTATTG
ERICH1-DPYD	chr8	618598	chr1	97700550	10	21	MPPGTAIRPIA	TGCCTCCTGGGACAGCAATCAGACCTATTGCTT
ERICH1-DPYD	chr8	618598	chr1	97700550	6	16	EHCTMPPGTA	AACATTGCACGATGCCTCCTGGGACAGCAA
ERICH1-DPYD	chr8	618598	chr1	97700550	6	17	EHCTMPPGTAI	AACATTGCACGATGCCTCCTGGGACAGCAATCA
ERICH1-DPYD	chr8	618598	chr1	97700550	7	17	HCTMPPGTAI	ATTGCACGATGCCTCCTGGGACAGCAATCA
ERICH1-DPYD	chr8	618598	chr1	97700550	8	17	CTMPPGTAI	GCACGATGCCTCCTGGGACAGCAATCA
ERICH1-DPYD	chr8	618598	chr1	97700550	8	18	CTMPPGTAIR	GCACGATGCCTCCTGGGACAGCAATCAGAC
ERICH1-DPYD	chr8	618598	chr1	97700550	9	17	TMPPGTAI	CGATGCCTCCTGGGACAGCAATCA
ERICH1-DPYD	chr8	618598	chr1	97700550	9	18	TMPPGTAIR	CGATGCCTCCTGGGACAGCAATCAGAC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ERICH1-DPYD

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
Non-Cancer	ERICH1-DPYD	chr8	618598	ENST00000262109	chr1	97700550	ENST00000370192	TCGA-BH-A0DL-11A

Top

Potential target of CAR-T therapy development for ERICH1-DPYD

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ERICH1-DPYD

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ERICH1-DPYD

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)